Universal CAR-T cells take on lupus and more in early trial
NCT ID NCT07246096
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and potentially reset the immune system. The main goals are to check safety and see if it can control disease activity. About 60 adults aged 18 to 70 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changhai Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers